Biotechnology News and Research RSS Feed - Biotechnology News and Research

CFDA accepts WuXi MedImmune's novel anti-IL6 monoclonal antibody IND application for review

CFDA accepts WuXi MedImmune's novel anti-IL6 monoclonal antibody IND application for review

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that an Investigational New Drug (IND) application for WuXi MedImmune's novel anti-IL6 monoclonal antibody for rheumatoid arthritis has been accepted for review by the China Food and Drug Administration. [More]
New Ebola vaccine shows promise in first phase 1 clinical trial

New Ebola vaccine shows promise in first phase 1 clinical trial

Results from the first phase 1 trial of an Ebola vaccine based on the current (2014) strain of the virus are today published in The Lancet. Until now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. The results suggest that the new vaccine is safe, and provokes an immune response in recipients, although further long-term testing will be needed to establish whether it can protect against the Ebola virus. [More]
Updated guidelines for diagnosis, treatment of medullary thyroid carcinoma released

Updated guidelines for diagnosis, treatment of medullary thyroid carcinoma released

A Task Force convened by the American Thyroid Association released updated guidelines for the diagnosis and treatment of medullary thyroid carcinoma (MTC). The current document is the first revision of the original guidelines published in 2009. [More]
Brainstorm Cell Therapeutics provides business update, announces financial results for 2014

Brainstorm Cell Therapeutics provides business update, announces financial results for 2014

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014. [More]
Mount Sinai researchers reprogram blood cells into iPSCs to study genetic origins of MDS

Mount Sinai researchers reprogram blood cells into iPSCs to study genetic origins of MDS

Induced pluripotent stem cells (iPSCs) -- adult cells reprogrammed back to an embryonic stem cell-like state--may better model the genetic contributions to each patient's particular disease. In a process called cellular reprogramming, researchers at Icahn School of Medicine at Mount Sinai have taken mature blood cells from patients with myelodysplastic syndrome (MDS) and reprogrammed them back into iPSCs to study the genetic origins of this rare blood cancer. [More]
Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

THERAVECTYS, a clinical development biotechnology company that focuses on the development of therapeutic vaccines and immunotherapies, proudly announces that its manufacturing plant has obtained the status of a pharmaceutical manufacturing establishment, granted by the French National Agency for Medicines and Health Products Safety. [More]
Accelovance named finalist for Best Contract Research Organization at ViE Awards

Accelovance named finalist for Best Contract Research Organization at ViE Awards

Accelovance, a therapeutically focused contract research organization (CRO), has been named a finalist for "Best Contract Research Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards hosted by the World Vaccine Congress. [More]

Marken secures Best Life Science Logistics Provider award

Marken announced today that they won the pharmaceutical clinical research industry award of Best Life Science Logistics Provider at the 5th Annual BioPharma Asia Industry Awards. The award was announced at a dinner and ceremony held in conjunction with the BioPharma Asia conference in Singapore, drawing an annual attendance of 1600. [More]
Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for treatment of gynecological cancers

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for treatment of gynecological cancers

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian, fallopian tube and primary peritoneal cancers. [More]
TxCell to present at upcoming US and French investment conferences

TxCell to present at upcoming US and French investment conferences

Damian Marron, CEO, TxCell, will present at the Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day, New York, March 25, 2015. In addition, Damian Marron will also participate at the Portzamparc PEA-PME Forum, Paris, April 1, 2015. [More]
Biologists identify new mechanisms linked to progression of aggressive form of dementia

Biologists identify new mechanisms linked to progression of aggressive form of dementia

Research by biologists at the University of York has identified new mechanisms potentially driving progression of an aggressive form of dementia. [More]
TGAC plans to use miniaturised sequencing device to conduct live environmental surveillance

TGAC plans to use miniaturised sequencing device to conduct live environmental surveillance

As one of the first research Institutes to take part in the MinION Access Programme (MAP) for portable DNA sequencing, introduced by Oxford Nanopore Technologies, The Genome Analysis Centre (TGAC)'s task force share their experience of the ground breaking trial so far. [More]
Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals. [More]
Globavir, BioManguinhos partner to jointly evaluate PanGlob RT-PCR Dengue diagnostic assay

Globavir, BioManguinhos partner to jointly evaluate PanGlob RT-PCR Dengue diagnostic assay

Globavir Biosciences, Inc., a biotechnology company developing diagnostic and therapeutic technologies to treat infectious diseases, has announced a partnership with BioManguinhos, a division of the Oswaldo Cruz Foundation, for a joint evaluation of Globavir's PanGlob RT-PCR Dengue diagnostic assay. [More]
Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol

Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol

Amgen today announced that an application seeking marketing approval of Repatha (evolocumab) for the treatment of high cholesterol has been submitted for review to the Ministry of Health, Labour and Welfare in Japan. [More]

Canfield to become sole supplier of PRIMOS family of 3D optical systems worldwide

Demonstrating its commitment to delivering best-in-class clinical research solutions, Canfield Scientific has been named the exclusive worldwide distributor of the highly respected PRIMOS family of 3D optical systems. [More]
Milk protein comparison study may help improve infant formula

Milk protein comparison study may help improve infant formula

Human babies appear to need more of a nutritional boost from breast-milk proteins than do infants of one of their closest primate relatives, suggests a study comparing human milk with the milk of rhesus macaque monkeys. [More]
Researchers successfully generate cells of immune system to target, destroy cancer cells

Researchers successfully generate cells of immune system to target, destroy cancer cells

Researchers at the Max Delbrück Center for Molecular Medicine Berlin-Buch and Charité - Universitätsmedizin Berlin, Campus Berlin-Buch, have succeeded in generating cells of the immune system to specifically target and destroy cancer cells. [More]
UF pharmacy dean to be honored with 2015 SURA Distinguished Scientist Award

UF pharmacy dean to be honored with 2015 SURA Distinguished Scientist Award

SURA today announced that Julie A. Johnson, Dean and Distinguished Professor at the University of Florida's College of Pharmacy, will receive its 2015 SURA Distinguished Scientist Award. [More]
3D printed heart models to aid doctors plan for complex ops'

3D printed heart models to aid doctors plan for complex ops'

A team of doctors at Cincinnati Children’s Hospital Medical Center are exploring new avenues to improve surgical preparations and patient care. The hospital recently partnered with the University of Cincinnati’s College of Engineering and Applied Science (CEAS) to produce a 3D printed heart model of a patient with a rare, life-threatening heart condition. 3D printed anatomical models derived from patient scans enable doctors to “practice” surgery in advance and assess possible complications for delicate procedures, improving the outcome of operations. [More]
Advertisement
Advertisement